A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase 2 clinical trial. If approved, the drug, called MariTide, could make Amgen the first new entrant into a market that’s been dominated by Novo Nordisk, which makes Ozempic and Wegovy, and Eli Lilly, which makes Mounjaro and Zepbound.
A dozen volunteers with severe type 1 diabetes showed clear improvements in their condition 12 months after receiving a revolutionary stem cell treatment, with all but two dropping their insulin therapy altogether. The phase 1/phase 2 clinical trial results provide hope for the 8.4 million people around the world with type 1 diabetes.
The question in this relatively new and burgeoning field is where to place your chips so you gain the best return long-term: with the top company, Intuitive Surgical, or a scrappy underdog, such as SS Innovations. There’s a good case to be made for the underdog.
Predicting trends and offering suggestions to help systems work more efficiently are both features of current artificial intelligence platforms, and Connecticut health experts are seeking new ways to make the technology work to improve care.
In a discovery that could reshape how we view and understand the human brain, researchers have successfully passed a laser beam through an entire human head. While it may sound like science fiction, this quiet milestone could pave the way for faster, cheaper, and noninvasive brain scans.